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Summary Expression of Bcl-2 is life-sustaining for small-cell lung cancer cells and associated with drug resistance. In the present study. the
interactions between the bc/-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin
were investigated on small-cell lung cancer cell lines to search for synergistic combinations. The cell lines NCI-H69, SW2 and NCI-H82
express high, intermediate-high and low basal levels of Bci-2, respectively, which are inversely correlated with the sensifivities of the cell
lines to treatment with oligodeoxynucleotide 2009 and the chemotherapeutic agents alone. Moreover, differences were found in the
responsiveness of the cell lines to treatment with combinations of oligodeoxynucleotide 2009 and the chemotherapeutic agents. In the cell
lines NCI-H69 and SW2, all combinations resulted in synergistic cytotoxicty. In NCI-H69 cells, maximum synergy with a combination index of
0.2 was achieved with the combination of oligodeoxynucleotide 2009 and etoposide. In SW2 cells, the combination of oligodeoxynucleotide
2009 and doxorubicin was the most effective (combination index = 0.5). In the cell line NCI-H82, which expresses a low basal level of Bc1-2,
most of the combinations were slightly antagonistic. Our data suggest the use of oligodeoxynucleotide 2009 in combination with
chemotherapy for the treatment of small-cell lung cancer that overexpresses Bcl-2.
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Lunc cancer is the leading cause ofcancer death. and its incidence
continues to rise worldwide. The treatment of small-cell lung
cancer (SCLC). which makes up about 25% of lunc cancer cases.
relies on different classes of chemotherapeutic agents. including
epipodophyllotoxins. anthracyclines and platinum analogtues.
Although the introduction of combination chemotherapy as the
principal form of treatment has led to an increase in median
sunrival. only a small proportion of patients with SCLC are cured
(Souhami and Las-. 1990).
Mechanisms of drucg resistance in solid tumours haxe been
examined extensixel over the last 10 years. In lung cancer cell
lines selected in vitro grenetic chanoes have been identified that
alter drug transport and activity. such as overexpression of the P-
glycoprotein or the multidrug resistance-associated protein (MRP)
(Dovle. 1993: Gonzalez Manzano et al. 1996: Versantxoort et al.
1996). However. no correlation between overexpression of these
drug transporters in lung, cancer cells and response to therapy has
been found in patients (Lai et al. 1989) suggesting that other
mechanisms are more important for chnical drug resistance of
lung cancer. It is now generally accepted that resistance to cyto-
toxic treatments relates to failure of cells to engyage the process of
apoptosis. and some of the genetic defects that antagonize apo-
ptosis have alreadv been unravelled. Most SCLC cell lines and
tumour tissues overexpress the Bcl-2 oncoprotein (Ben Ezra et al.
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1994: Reeve et al. 1996). Ahich has been associated Awith
chemotherapy resistance of various tumour cells in xitro and in
vivo (Campos et al. 1993: Kamesaki et al. 1993: Mivashita and
Reed. 1993: Strasser et al. 1994). For example. ectopic expression
of bcl-2 has been shown to confer resistance to etoposide and
cisplatin in neuroblastoma and lymphoma cell lines (Mis-ashita
and Reed. 1992: Dole et al. 1994: Strasser et al. 1994). and to
doxorubicin in a SCLC cell line (Ohmori et al. 1993).
Modulation of gene expression by antisense oligodeoxy-
nucleotides (ODNs) is a promising approach because of its target
specificity and potential applicability to any sequenced gene The
mechanisms implicated in the action of antisense ODNs relate to
RNase H-mediated hydrolysis of the target mRNA or to trans-
lational arrest anrsing from steric hindrance by the RNA-DNA
heteroduplex (Stein and Cheng. 1993: Ho and Parkinson. 1997).
These mechanisms differ greatly from those exerted by chemo-
therapeutic arents and thus might operate also in drum-resistant
tumour cells. Antisense ODNs targeting the first six codons of the
bcl-2 mRNA have been show-n to increase the sensitivity of
lymphoma cells to chemotherapeutic acents (Kitada et al. 1994).
However. althouth the combination of bcl-2 antisense ODNs and
chemotherapy seems to be appealing. the cytotoxic interaction of
these treatments on tumour cells has not yet been addressed in
detail. Recently. we has-e identified an antisense sequence (ODN
2009) targeting the bcl-2 coding region that effectixelv down-
regulated bcl-2 expression and induced apoptosis in SCLC cells
(Ziegler et al. 1997). In the present study. we examined the cyto-
toxic effects ofODN 2009 in combination with etoposide. doxoru-
bicin and cisplatin on SCLC cell lines with different Bcl-2 levels.
Analysis ofpotential synergy w-as performed by the median effect
method described by Chou and Talalay ( 1984).
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MATERIALS AND METHODS
Cell lines
The SCLC cell line S'W2 was obtained from the Dana-Farber
Cancer Institute. Boston. NMA. USA. The SCLC cell lines NCI-
N417. NCI-H82 and NCI-H69 were obtained from the American
Tyvpe Culture Collection (ATCC: Rockville. ND. USA). Cells
w-ere cultured in RPMI-1640 (Hvclone Europe. Cramlington. UK)
supplemented with 2 mM1 L-glutamine. 10%7c fetal calf serum (FCS)
(Hyclone Europe). 50 lU ml-' penicillin and 50 go, ml-' strepto-
mycin (cell culture medium) at 37-C in a humidified atmosphere
xxith 5% carbon dioxide.
Bcl-2 antisense and control ODNs
The 20-mer phosphorothioate ODN 2009 wxith the sequence 5'-
AATCCTCCCCCAGTTCACCC-3' targets the coding region of
the bcl-2 mRNA (Ziegler et al. 1997). The following ODNs were
used as controls: sense 5'-GGGTGAACTGGGGGAGGATT-3'.
5'-3' rexersed 5'-CCCACTTGACCCCCTCCTAA-3'. the scram-
bled sc-21 5'-ACACCCCAATTCTlTCCGCCC-3' and the four base
mismatch 5'-AATCCTCCGGCCTCTTCACCC-3'. A BLASTN'
search of a database containgnc all sequences of GenBank. ENBL.
DDBJ and PDB rexealed no homolocgy of the control ODNs to
human genes. All ODNs wxere provided by Genset (Paris. France)
as 'guaranteed oligos. They had been purified by use of a Uaters'
high-pressure liquid chromatography svstem equipped w-ith a
Nucleosil C column and a mobile phase consisting of a 15-25%
gradient of acetonitrile. Purified ODNs were stored at -'20C in
10 inst Tris. pH 7.4. containicr 1 nvm EDTA.
Delivery of ODNs to SCLC cells
ODN 2009 and the control ODN sc-21 were delivered to cells
in the form of complexes w-ith the cationic lipid N-[1-(2.3-
dioleoy loxy )propxl]-AN.N.V-trimethv-lammonium methylsulphate
(DDOTAP: Boehrinrer MIannheim. Germany) essentiallx as
described prexiously (Ziegler et al. 1997). Briefly. equal volumes
of ODNs (24 jm) and DOTAP (400 Im) in 20nmm HEPES-
buffered saline were mixed and allowed to complex for 10 min at
room temperature. The mixtures were diluted into nine volumes of
cell culture medium to achieve solutions of 1.2 jmI ODN. For use
in experiments. ODN stock solutions were further diluted serially
into cell suspensions containing medium alone or medium with
various dilutions of the chemotherapeutic agents.
Western blot analysis
Western blottingxwas performed as described by Ziegler et al
(1997). Briefly. 1 ml ofcells/ODN mixture wxas plated in a 24-xxell
plate and incubated for 24 h at 37TC. ODN concentrations and cell
densities were as above. Ten iga of soluble protein extract per
sample was separated on a 12% polvacrxlamide sodium dodecyl
sulphate (SDS) cgel at 150 V for about 3 h. and transfer to a
polyvinylidene fluoride membrane (Immobilon-P. Millipore) was
performed in a semi-drx blotting chamber (Schleicher and
Schuell) at 1 mA cm- for 1 h. The blots x-ere blocked in Tris-
buffered saline (TBS) containino 5%'7 bovine serum and 5%7c non-
fat drx milk. and then incubated oxernight at 4 C with mouse
anti-human Bcl-2 monoclonal antibodx (Dako Diagnostics.
Glostrup. Denmark). To detect the primarx antibody. blots wxere
incubated wkith a rabbit antimouse immunoglobulin peroxidase
conjugate (Sigma Chemical. St. Louis. MO. USA) for 2 h at room
temperature. Visualization of the immunocomplex xx-as performed
by enhanced chemiluminescence using the ECL kit (Amersham).
followed by exposure to radiographic films (Fuji RX) for different
time periods dependent on the cell line. Relative protein levels
were quantified after scanning ofthe films using a flat bed scanner
(Hewlett Packard ScanJet Hcx) and the ImageQuant software
(Molecular Dvnamics.)
Chemotherapeutic agents
Doxorubicin (Adnrblastine) was obtained from Farmitalia Carlo
Erba (Zug. Switzerland). Etoposide (Vepesid) and cisplatin
(Platinol) were obtained from Bristol-Myers Squibb (Baar.
Switzerland). All agents were clinical grade and diluted with cell
culture medium before use.
Measurement of cell viability
The cytotoxic effects of ODN 2009 and chemotherapeutic agents
on SCLC cell lines were determined by use of the colorimetric
WST-1Iiabilitx assav as described previously (Ziegler et al. 1997).
Once the optimal growth conditions have been established for each
cell line. the WST-1 viabilitv assav provides reproducible results
which correlate well with the actual number of X iable cells deter-
mined by propidium iodide exclusion (Ziegler et al. 1997). Briefly.
for each experiment. 100gl each of cell suspensions containing
ODN 2009 or control ODNs. the chemotherapeutic agents. or a
combination ofboth types ofagents were plated in triplicates in 96-
well plates. Cell densities were 0.5 x 105 cells ml (SW2. NCI-
H82). or I0- cells ml' (NCI -H69). Cells were incubated for4 days
at 37 C. and then 10 gl ofWST-1 reagrent (Boehringer Mannheim.
Germanv) was added per well and allowed to react for 3-5 h at
37"C. Absorbance at 450 nm was measured by use of an enzx-me-
linked immunosorbent assav reader (2550 EIA reader. Bio Rad
Laboratories. Hercules. CA. USA).
Determination of viable cell numbers based on
propidium iodide exclusion
To determine the number of x-iable cells after cytotoxic treatment.
4 ml of cell suspensions containing ODN 2009. chemotherapeutic
agents or a combination ofboth types ofagents were plated in six-
well plates. The same cell densities as for the WST-1 viabilitx
assay described above were used. At different time points ofincu-
bation. cells were harnested. briefly trvpsinized and resuspended
in phosphate-buffered saline (PBS). Immediately before measure-
ment. propidium iodide was added to a final concentration of
1.25 jge ml . The number ofcells in the cultures was quantitated at
a constant flow rate of 12 ' a mmn-I by use of a FACSCalibur cvto-
fluorometer (Becton Dickinson. Mountain View. CA. USA). Only'
cells that excluded propidium iodide were considered Xiable.
Apoptotic cell death after cvtotoxic treatment was confirmed by
forward and side light scatter analy-sis as described prexviouslV
(Cotter et al. 1992: Ziegler et al. 1997).
Analysis of combined ODN/drug effects
The median-effect method described by Chou and Talalay (1984)
was used to determine the nature of interaction betxxeen ODN
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Figure 1 Westem blot analysis of Bcl-2 protein in SCLC cell lines after
treatment with antisense ODN 2009 or the control ODN sc-21. Cells were
incubated for 48 h with medium alone (control) or with 75 nu or 150 nm ODN
2009 or ODN sc-21. Ten micrograms of soluble protein were analysed per
sample and Westem blotting was performed as described in the Materials
and methods section. Blots were exposed to radiographic films for 5 min
(NCI-H69 and SW2 cells). or 40 min (NCI-H82 cells)
Table 1 Cytotoxicity of ODN 2009 and chemotherapeutc agents on SCLC
cell lines
lC50 t s.d. (nu)
Relative Bcl-2
Cell line level (%) ODN 2009 Etoposide Doxorubicn Cispain
SW2 100 48-8 12000+900 37 4 2100+100
NCI-H69 174 ± 21 135 20 16000± 2000 80 + 8 5000 ±400
NCI-H82 23 _ 4 32 5 590± 60 11 + 1 680 _40
aQuantitated from Western blots.
2009 and the chemotherapeutic agents. This analysis is based on
the median-effect principle of the mass action law and relies on
linear regression as a well-accepted statistical approach. In each
experiment, cells were treated with serial dilutions of ODN 2009
and drugs individually. and with fixed ratios of ODN 2009 and
drugs simultaneously at doses in the range of the indi-idual
concentrations at which cell viabilitv was inhibited bN 50% (IC*).
The fraction affected (f) was calculated by dividing the per cent
v-iabilits in ODN 2009 and drug-treated wells by the viability in
untreated wells. and data were analysed by the median-effect
method (Chou and Talalay. 1984). Briefly. log (l/fa-lI) was plotted
against log(drug dose). From the resulting median-effect lines. the
x-axis intercept (loc IC ) and slope m w-ere calculated for ODN
2009 and each drug, and for the combinations by the least squares
method. Wkhen ODN 2009 and drugs x-ere administered at a fixed
ratio. the dose of the combination required to producefa could be
separated into the component doses (D)1 and (D)2 of ODN 2009
and drug, respectixvely. For each level of cvtotoxicitx. a combina-
tion index (OC) was calculated atincreasing, cell kill and the combi-
nations were compared with the cytotoxic effects of the respective
sinale agent treatments in each experiment. Synergy is indicated
by a CI less than 1. additixitv by a CI equal to 1. and antaconism
by a Cl greater than 1. For each combination. CI-values w-ere
calculated based on the assumption that drug interaction w-as
mutually exclusixe and mutually non-exclusive (cuhen drugs have
different modes of action or act independently). Because wve did
not map the entire response surface (Greco et al. 1995). the data of
interaction of ODN 2009 with the chemotherapeutic agents calcu-
lated for each cell line rely on the fixed ratios ofthe agents.
RESULTS
Bcl-2 levels in SCLC cell lines and effect of treatment
with ODN 2009
To demonstrate the abilitv of ODN 2009 to doxxn-regulate Bcl-2
expression in the SCLC cell lines. Westem blot analy sis was
performed. Cells were incubated for 48 h with 75 nr\I or 150 nmt
ODN 2009. Untreated cells were used to determine the basal levels
of Bcl-2 in the cell lines. The relative basal levels of Bcl-2 which
w-ere quantitated from the Western blots are shown in Figure 1.
Bcl-2 was abundantly expressed in the cell lines NCI-H69 (174%7c)
and SW2 (100%c). but A-as barely detectable in the NCI-H82 cell
line (23%). As show-n in Fioure 1. in all cell lines ODN 2009
caused a dose-dependent reduction in Bcl-2.
Cytotoxicity of single agents
The IC<, -alues of ODN 2009. etoposide. doxorubicin and
cisplatin were determined for the SCLC cell lines SW2. NCI-H69
and NCI-H89 using the WST-1 assay. As shown in Table 1. there
was an inverse correlation betxween the lexel of Bcl-2 and the
sensitivitv of the cell lines to all three chemotherapeutic agents
tested (0.02 > P > 0.007).
Interaction between ODN 2009 and chemotherapeutic
agents on SCLC cells expressing intermediate levels of
Bcl-2
The dose-response curses and median-effect plots for the treat-
ment of SW2 cells that express intermediate lexels of Bcl-2
(Figure 1. Table 1) with the different agents are depicted in Figaure
2. No effect on cell viabilitv Axas seen w-ith the ODNs sc-21 and
sense. whereas the ODNs mismatch and 5'-3' reversed slightly
reduced the number of viable cells at concentrations higher than
80 n\. WNhen cells were exposed to fixed ratios ofODN 2009 and
etoposide (1:330). doxorubicin (1:1) or cisplatin (1:83) at doses
that roughly corresponded to the IC; values. the cytotoxic effects
of the combinations were alwavs greater than those obser ed w-ith
the sinale aaents alone (0.03 > P > 0.01). When used in combina-
tion w-ith etoposide. doxorubicin or cisplatin at concentrations
equivalent to ODN 2009. none of the control ODNs could poten-
tiate the cytotoxic effects ofthe chemotherapeutic agents. Median-
effect analysis of the cytotoxicit- data demonstrated linear cun-es
W-ith similar slopes for ODN 2009 and etoposide and different
slopes for doxorubicin and cisplatin (Figure 2). This suggests the
interaction of ODN 2009 to be mutually exclusive with etoposide
and mutually non-exclusive w-ith doxorubicin and cisplatin (Chou
and Talalay. 1984). As calculated from the median-effect curxes in
Ficure 2. the CI values of the treatment of SW2 cells with ODN
2009 and etoposide were about 0.6 ± 0.1 at all levels of toxicits
(Figure 3). Likewise. treatment of SW2 cells with ODN 2009
in combination with doxorubicin and cisplatin also resulted in
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Figure 2 Cytotoxicity of ODN 2009, etoposide, doxorubian and cisplabn alone, or their combinabons on SW2 cells. Cells were incubated with ODN 2009, control
ODNs or chemothrapeutic agents alone, and with combinabons of ODN 2009 or control ODNs and chemotherapeutic agents at the ratos indcated. The percentage
of viable cells determined by using the WST-1 assay was plotted relative to untreated control cels. The median-effect plots were derved form the dose-response
curves of the combinabons and were used to calculate the combination index (CI) values shown in Figure 3. Dose-reponse data represent the means of three
independent determinabons from which the median-effect plots were calculated: line bars = s.d. The cytotoxic effects of ODN 2009 and control ODNs, and of the
combinabons of ODN 2009 and control ODNs with chemotherapeutic agents were significantly different (P < 0.01) as detenrmined by two-sided t-tests
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Figure 3 Cl plots of the combinat of ODN 2009 with the chemtherapeutic agents on the three SCLC cesl lines. The combination index (Cl) values were
calculated from median-effect plos of the combination treatments as shown for SW2 cells in Figure 1 and represent the means. On SW2 and NCI-FH69 cells, the
ratios of ODN 2009 and etoposide, doxorubicin and cisplatin were 1:330, 1:1 and 1:83 respectively. On NCI-H82 cells. ODN 2009 was combined with etoposide.
doxorubicin and cisplatin at ratios of 1:43, 4:1 and 1:43 respectively (f, fracton affected; f , fracon unaffected). The solid line represents mutually non-
exclusive interacton, the dotted line mutualty exclusive interaction of the agents
synergistic activity with mean CI values of 0.6 ± 0.08 and 0.83
0.07 respectively (Figure 3).
To support the observation of synergistic cytotoxicity between
ODN 2009 and the chemotherapeutic agents by a different cell
viability assay. flow& cytometric analysis based on propidium
iodide exclusion of cells was performed for the combination of
ODN 2009 and doxorubicin on SW2 cells. As shown in Figure 4A.
the combination of ODN 2009 (75 nM) and doxorubicin (6.3 nm)
reduced the number of viable SW2 cells to 10% of the untreated
control during a 96-h treatment. Although synergistic cytotoxicity
cannot be directly deduced from the viability curves. it is obvious
that this combination was significantly more cytotoxic to the cells
than treatment with equivalent concentrations of ODN 2009 or
doxorubicin alone (P < 0.003). In contrast. the effects of a combi-
nation of ODN mismatch and doxorubicin. and doxorubicin alone
were not significantly different (P > 0.2). This indicates that poten-
tiation of the cytotoxicity of doxorubicin was specific for ODN
2009 and its ability to down-regulate bel-2 expression.
To demonstrate morphological changes of the cells typical for
apoptosis. SW2 cells were subjected to forward and side light
scatter analysis 72 h after treatment with 75 nM ODN 2009 in
combination with 6.3 nm doxorubicin. As shown by the contour
plots in Figure 4B. the treatment caused an obvious increase in
side light scattering and a slight reduction in forward light
scattering of the cells. Microscopic analysis of the treated cells
revealed shrinkage, extensive plasma membrane blebbing and
nuclear condensation (not shown).
Interaction between ODN 2009 and chemotherapeutic
agents on SCLC cells expressing high levels of Bcl-2
Compared with the other cell lines used in this study. the NCI-H69
cell line has the highest level of Bc1-2 (Fioure 1. Table 1).
Treatment ofthese cells with ODN 2009 was synergistic in combi-
nation with etoposide. doxorubicin and cisplatin at all levels of
toxicity. The slopes of the median-effect curves (data not shown)
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Figure 4 Quantification and morphology analysis of SW2 cells after
treatment with ODN 2009 and doxorubicin by flow cytometric analysis.
(A) Cells were treated with ODN 2009, ODN mismatch or doxorubicin alone,
and with ODN 2009 or ODN mismatch in cormbination with doxorubicin.
Viable cells were quantitated based on propidium iodide exclusion at different
time points and expressed as per cent of untreated cells (control). Data
represent the means ± s.d. of three independent determinations. (B) Contour
plots of untreated SW2 cells and SW2 cells 72 h after treatment with ODN
2009. or ODN 2009, and doxorubicin in combination. Results from flow
cytometric analysis are plotted as forward light scatter (FSC) against side
light scatter (SSC) intensity. Morphologically intact cells localize in the lower
right quadrant. apoptotic cells have shifted to the upper nght comer
suggest a mutuallx exclusive interaction for ODN 2009 and
doxorubicin. and mutuallx non-exclusive interactions for the other
combinations. When cells were exposed to a fixed 1:330 ratio of
ODN 2009 and etoposide. the CI v-alues of the interaction were
0.2 ± 0.05 at the ICK,C and 0.9± 0.1 at the IC90 of the combination
(Figure 3). Cytotoxic effects more than additive over the whole
range of toxicitv were also obtained for the combination of ODN
2009 w ith doxorubicin at a ratio of 1:1. and with cisplatin at a ratio
of 1:83 (Figure 3.
Interaction between ODN 2009 and chemotherapeutic
agents on SCLC cells expressing low levels of Bcl-2
Compared with the cell lines SW2 and NCI-H69. the NCI-H82
cell line has barely detectable Bcl-2 levels (Figure 1. Table 1). The
different slopes of the median-effect curves (data not show-n)
suggest that on this cell line all combinations resulted in mutuall1
non-exclusive interactions. As shown in Finure 3. the combination
of either ODN 2009 and etoposide at a ratio of 1:43 or ODN 2009
and doxorubicin at a ratio of4:1 % as slightiv less than additive and
resulted in antagonistic effects (CI> 1 ) at all lesels of toxicity.
Synergistic cytotoxicitv on NCI-H82 cells A-as obtained only if
ODN 2009 was combined with cisplatin (1:43) at the IC,0 and
the ICR) of the combination with CI salues of 0.72 ± 0.08 and
0.95 ± 0.1 respectivelx (Figure 3.)
DISCUSSION
Etoposide. doxorubicin and cisplatin are routinel1 used for the
treatment ofSCLC. Thev Aork- bv damaging, DNA w-hich tric-aers a
common death programme called apoptosis (Strasser et al. 1994).
The Bcl-2 oncoproteim can counteract drug-induced apoptosis and
its expression has been associated xxith multidrucg resistance in a
varietv of tumour cells (Mix ashita and Reed. 1993: Ohmori et al.
1993: Dole et al. 1994: Strasser et al. 1994). Here. we report on the
cytotoxic effect of antisense-mediated down-regulation of bcl-2
expression in combination w-ith etoposide. doxorubicin and
cisplatin on three SCLC cell lines. Bcl-' is abundantlx expressed in
the cell line NCI-H69. whereas intermediate-high and low levels
are present in the cell lines SW2 and NCI-H82 respectively
(Ziegler et al. 1997). We obser ed an inverse correlation ofthe Bcl-
2 levels of these cell lines w-ith the sensitivities to the chemo-
therapeutic agents tested. This suggests that Bcl-2 is critical for
inhibiting drug-induced apoptosis in SCLC cells.
Antisense ODNs have been used to disrupt the expression of
various cancer related genes and to inhibit tumour cell growth in
preclinical studies (Dosaka Akita et al. 1995: Monia et al. 1996:
Kitada et al. 1994: Szczvlik et al. 1991). and first results of anti-
tumour actixitv are also available from clinical studies (Webb et al.
1997). ODN 2009 is a 20-mer phosphorothioate that targ-ets the
coding regionofthe bcl-2 mRNA (Ziecleret al. 1997). In SCLC cells
it effectivelydown-regulated bcl-2 expression and induced apoptosis
to a degree inversely correlated with the level of expression. This
suggests Bcl-2 to be a critical sur-ixal factor for SCLC cells.
Combination chemotherapy has become the standard treatment
for SCLC (Souhami and Law. 1990). The cytotoxic interactions of
various chemotherapeutic agents have been analysed in xitro bv
different calculation methods (Kaufmann et al. 1996: Photiou et al.
1997). and it has been show-n that even clinicallx approved drug
combinations mayresult in less than additive effects (Kaufmann et
al. 1996). These findings imply that such in vitro studies migCht be
useful for the selection and design of optimal druga combinations
forclinical application. Combinations ofantisense ODNstargeting
specific oncogenes or gyenes involved in drug, resistance. such as
bcl-2. and less toxic doses ofchemotherapeutic agents represent a
rational therapeutic strategy to pursue. In models of human
leukaemia and colon carcinoma xenografts in mice. it has been
shown that antisense ODNs targeting the oncogenes berlabl
(Skorski et al. 1997) or c-mvb (Del Bufalo et al. 1996). or the
multiple drug resistance gene mdrl (Cucco and Calabretta. 1996)
can indeed enhance the anti-tumour effect of chemotherapeutic
agents. However. these studies did not directly insvestioate the
interaction ofthe antisense ODNs with chemotherapeutic agents in
vitro and did not search for synergistic combinations.
In the present study. w-e demonstrate for the first time that a
combination of bcl-2 antisense ODN with etoposide. doxorubicin
or cisplatin results in synergistic cytotoxicitv on cell lines derixed
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from a solid tumour in which Bcl-2 is prevalent (Ben Ezra et al.
1994). Synergy was particularly pronounced on the cell lines NCI-
H69 and SW2 that have high and intermediate-high Bcl-2 levels
respectively. The cell line NCI-H82 which expresses barely
detectable Bcl-2 levels was extremely sensitive to treatment with
ODN 2009 and also to the chemotherapeutic agents alone. This
miaht explain why. on this cell line. ODN 2009 and the
chemotherapeutic agents did not interact synergistically.
Because the sulphur backbone ofphosphorothioate ODNs non-
specifically interacts with proteins and nucleic acid targets (Stein
and Krieg. 1994: Stein. 1995). it is difficult to determine w-hich of
their bioloaical effects are truly antisense in nature. Therefore. in
the present study. a series of control phosphorothioate ODNs was
used for comparison to ODN 2009. At concentrations less than
150 n-. only the ODNs mismatch and 5'-3' reversed caused a
slight reduction in cell viability. In combination experiments. none
of the control ODNs potentiated the cytotoxic effects of the
chemotherapeutic agents. This unequivocally excludes the possi-
bilitv that the increase in cvtotoxicitv achieved w-ith the combina-
tions of ODN 2009 and chemotherapeutic agents was the result of
enhanced cellular uptake of the latter in the presence of cationic
lipids (Bennett et al. 1992).
Although the intracellular targets and the mechanisms of action
of ODN 2009 and the chemotherapeutic agents are different. their
effects eventually merge in a common final death pathw-ay. In this
case. one would expect the interactions between ODN 2009 and
etoposide. doxorubicin or cisplatin to be mutually exclusive. For
example. Bcl-2 has been shown to inhibit apoptosis induced by
etoposide through effects on events early after topoisomerase II-
induced DNA damage (Kamesaki et al. 1993). According to Chou
and Talalay ( 1984). agents are claimed to be mutually exclusive if
the slopes of the median-effect lines ofthe single-agents and their
combination are identical. Based on this assumption. however. on
S'W2 cells a mutually exclusive interaction occurred betueen
ODN 2009 and etoposide. but not between ODN 2009 and doxoru-
bicin or cisplatin. On NCI-H69 cells. only the interaction ofODN
2009 and doxorubicin is suggested to be mutually exclusive. This
indicates that: (1) cells can differ in the way they handle the apop-
totic signals provided by ODN 2009 and the chemotherapeutic
agents: (2) the assumption whether agents act independently or not
cannot be made solely based on our current understanding of the
initial steps in their mechanisms of action. Considerinc this uncer-
taintv. in the present study all data were analy-sed assuming both
mutually exclusive and non-exclusive interactions ofthe agents.
In considerinc the potential implication ofthis study. one limita-
tion must be kept in mind. The data for each cell line were gener-
ated using fixed ratios of the agents. If a different ratio had been
evaluated. a different CI plot would have resulted. Thus. because
the entire response surfaces (Greco et al. 1995) were not mapped.
the conclusions of the study are limited to the ratios of ODN
2009 and chemotherapeutic agents that were actually used.
Nevertheless. our data provide clear evidence that synergistic
interactions ofODN 2009 and the chemotherapeutic agents can be
expected to be more pronounced on cells expressino higher levels
of Bcl-2. It will be of interest to see to what extent the differences
bet-een synergistic and antagonistic effects observed in vitro
translate to in vivo responses.
Our data suggest the use of ODN 2009 in combination with
conventional chemotherapy as a novel approach to more effective
treatment of SCLC and other types of tumours in which Bcl-2 is
prevalent.
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